Stocktoria
Tevogen Bio Holdings Inc. TVGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-11-04
Tevogen Bio Holdings Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $11.1M | $31.0M | $4.4M | — |
| Operating income | -$26.1M | -$53.6M | -$8.8M | — |
| Interest expense | — | $184,037 | $1.2M | — |
| Income tax | $4,750 | $1,750 | — | — |
| Net income | -$26.3M | -$13.7M | -$60.5M | $4.4M |
| EPS (diluted) | $-8.08 | $-3.50 | $-2.44 | — |
| Operating cash flow | -$12.3M | -$12.0M | -$8.2M | -$215,395 |
| Free cash flow | -$12.4M | — | -$8.3M | — |
| Cash & equivalents | $0 | $0 | $0 | $129,186 |
| Total assets | $4.4M | $3.5M | $5.5M | $357.1M |
| Total liabilities | $12.6M | $10.1M | $99.9M | $15.1M |
| Shareholders' equity | -$8.2M | -$6.7M | -$94.4M | -$34.0M |
Source: SEC EDGAR filings · CIK 0001860871 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.